Now that Coherus Oncology Inc’s volume has hit 1.28 million, investors get a glimpse of its size.

Zack King

On Tuesday, Coherus Oncology Inc (NASDAQ: CHRS) opened higher 7.08% from the last session, before settling in for the closing price of $1.13. Price fluctuations for CHRS have ranged from $0.71 to $2.43 over the past 52 weeks.

It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -27.36%. Company’s average yearly earnings per share was noted -714.73% at the time writing. With a float of $102.19 million, this company’s outstanding shares have now reached $116.24 million.

Coherus Oncology Inc (CHRS) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Coherus Oncology Inc is 15.46%, while institutional ownership is 41.99%. The most recent insider transaction that took place on May 23 ’25, was worth 73,881. In this transaction Director of this company sold 99,988 shares at a rate of $0.74, taking the stock ownership to the 0 shares.

Coherus Oncology Inc (CHRS) Performance Highlights and Predictions

If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.28 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.13) by -0.15. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -714.73% per share during the next fiscal year.

Coherus Oncology Inc (NASDAQ: CHRS) Trading Performance Indicators

Check out the current performance indicators for Coherus Oncology Inc (CHRS). In the past quarter, the stock posted a quick ratio of 1.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.75.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.59, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.00 in one year’s time.

Technical Analysis of Coherus Oncology Inc (CHRS)

The latest stats from [Coherus Oncology Inc, CHRS] show that its last 5-days average volume of 1.55 million was inferior to 1.57 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.82%.

During the past 100 days, Coherus Oncology Inc’s (CHRS) raw stochastic average was set at 41.88%, which indicates a significant increase from 17.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1279 in the past 14 days, which was higher than the 0.0927 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.5502, while its 200-day Moving Average is $1.1026. Now, the first resistance to watch is $1.2700. This is followed by the second major resistance level at $1.3300. The third major resistance level sits at $1.4150. If the price goes on to break the first support level at $1.1250, it is likely to go to the next support level at $1.0400. Assuming the price breaks the second support level, the third support level stands at $0.9800.

Coherus Oncology Inc (NASDAQ: CHRS) Key Stats

There are currently 120,871K shares outstanding in the company with a market cap of 146.25 million. Presently, the company’s annual sales total 266,960 K according to its annual income of 28,510 K. Last quarter, the company’s sales amounted to 11,570 K and its income totaled -35,530 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.